Third generation dendritic cell vaccines for tumor immunotherapy.
about
Immune Cells in Cancer Therapy and Drug DeliveryTherapeutic cancer vaccines: past, present, and futureDendritic cell-based vaccine efficacy: aiming for hot spotsRole of fatty-acid synthesis in dendritic cell generation and functionAutologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients.Chemokines as Cancer Vaccine Adjuvants.Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.Dab2, a negative regulator of DC immunogenicity, is an attractive molecular target for DC-based immunotherapy.Efficiency of dendritic cell vaccination against B16 melanoma depends on the immunization route.RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1α release, and efficient paracrine dendritic cell activationEnhancement of the Immunostimulatory Functions of Ex Vivo-Generated Dendritic Cells from Early-Stage Colon Cancer Patients by Consecutive Exposure to Low Doses of Sequential-Kinetic-Activated IL-4 and IL-12. A Preliminary Study.Synergistic effect of methionine encephalin (MENK) combined with pidotimod(PTD) on the maturation of murine dendritic cells (DCs)Cancer nanoimmunotherapy using advanced pharmaceutical nanotechnology.The role of Toll-like receptor 4 polymorphisms in vaccine immune response.Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists.Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.Characterization of Interleukin-15-Transpresenting Dendritic Cells for Clinical Use.OK-432 synergizes with IFN-γ to confer dendritic cells with enhanced antitumor immunity.CD8(+) T-cell priming and boosting: more antigen-presenting DC, or more antigen per DC?
P2860
Q26747061-1F0E4244-C885-4BF1-B190-BEE614834007Q26863283-7F9A92DE-3FD2-407D-80C5-3B2494D68A33Q28082680-5230CE44-9042-44FA-A645-059B1E7D5892Q28397185-973D006C-6498-4AF1-9602-75B74A6E9CE9Q31157425-B79E957D-F1C3-4E9B-8478-BB119D656493Q33792344-4EFB83C8-535D-4447-9811-1E4CE15C44DEQ33820274-A5307DF6-3BA8-4D5B-B948-1D5985C0849BQ35201865-115C2B98-1CEC-4A71-9381-739E69F8548CQ35224721-58772EEE-E913-40F5-AA33-AE4AE2C236B9Q35832188-322F1E00-935C-49C3-A5C9-ADE3D4240A6AQ36038020-B8E7F7AA-E0C4-4561-A839-144335EE8319Q37521866-C0778D58-E67F-4871-95E6-F28BE9D375C3Q38285751-3181A915-E56C-4AA1-B660-0D48FDEF28B8Q38396207-9CC35CC0-4881-4F24-9972-8115335B9130Q38672403-451A3F94-88D5-44CB-B5B8-737A445E6E4AQ39015531-F8FE4122-C170-4449-BA0F-48CD913E9E91Q40102608-0113FD49-A0F6-4763-B77C-A20F0E5BB0C1Q45967667-C105EC6D-6E64-43E6-81E5-AB103BC9A072Q50471175-1C7B6F8A-BAB8-4261-B18D-90CB69B23589
P2860
Third generation dendritic cell vaccines for tumor immunotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Third generation dendritic cell vaccines for tumor immunotherapy.
@en
Third generation dendritic cell vaccines for tumor immunotherapy.
@nl
type
label
Third generation dendritic cell vaccines for tumor immunotherapy.
@en
Third generation dendritic cell vaccines for tumor immunotherapy.
@nl
prefLabel
Third generation dendritic cell vaccines for tumor immunotherapy.
@en
Third generation dendritic cell vaccines for tumor immunotherapy.
@nl
P1476
Third generation dendritic cell vaccines for tumor immunotherapy.
@en
P2093
Bernhard Frankenberger
Dolores J Schendel
P356
10.1016/J.EJCB.2011.01.012
P577
2011-03-25T00:00:00Z